---
document_datetime: 2024-03-13 12:29:52
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/blenrep-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: blenrep-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5050432
conversion_datetime: 2025-12-30 01:30:40.877731
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                              | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|--------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10869 /202302  | Periodic Safety Update EU Single assessment - belantamab mafodotin | 31/08/2023                                  | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                      |
| PSUSA/10869 /202208  | Periodic Safety Update EU Single assessment - belantamab mafodotin | 30/03/2023                                  | 26/05/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

Blenrep (EXP) Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |          | PSUSA/10869/202208.                                                                                                                                                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                              | 30/03/2023 | 26/05/2023 | SmPC     | Product information section 6.3 is updated to reflect the shelf-life extension of the finished product BLENREP 100 mg powder for concentrate for solution for infusion (EU/1/20/1474/001) as packaged for sale from 3 years to 4 years. authorised |
| IB/0016/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 07/02/2023 | n/a no     | longer   |                                                                                                                                                                                                                                                    |
| IB/0014             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation product                                                                                                                                                                                                                                            | 26/09/2022 | 26/05/2023 | Annex II |                                                                                                                                                                                                                                                    |
| PSUSA/10869 /202202 | Periodic Safety Update EU Single assessment - belantamab mafodotin                                                                                                                                                                                                                                                                                                                               | 01/09/2022 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                  |
| IB/0013             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS Medicinal                                                                                                                                                                                                                                                                       | 16/08/2022 | n/a        |          |                                                                                                                                                                                                                                                    |
| IB/0012             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                       | 14/07/2022 | n/a        |          |                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| R/0010              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                     | 22/04/2022   | 29/06/2022 no   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Blenrep, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. SmPC section 5.3 Preclinical data is being updated to reflect new data from the ocular toxicity study in rabbits (Report 2021N465838). The following sentence is added: 'Inflammation of the corneal stroma correlating with superficial haze and vascularisation was observed in rabbits'. In addition, the MAH has amended the ATC code (L01FX15) according to the updated WHO classification. longer authorised   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10869 /202108 | Periodic Safety Update EU Single assessment - belantamab mafodotin                                                                                                                                                                                                                                          | 24/03/2022   | 30/05/2022      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10869/202108.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0009/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation Medicinal product | 25/02/2022   | n/a             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0008/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                          | 11/02/2022   | n/a             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | longer authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006/G | This was an application for a group of variations. Amendments to the marketing authorisation In view of the data submitted with the group of variations, amendments to Annex(es) I, IIIA and IIIB are recommended. 3. EPAR changes The table in Module 8b of the EPAR will be updated as follows: Scope Please refer to the Recommendations section above C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to 13/01/2022 Medicinal product no                         | SmPC, Labelling and PL SmPC new text Section 4.4: Warning on Pneumonitis is added: Cases of pneumonitis from spontaneous reports and named patient programs, including fatal events, have been observed with BLENREP although a causal association has not been established. Evaluation of patients with new or worsening unexplained pulmonary symptoms (e.g. cough, dyspnea) should be performed to exclude possible pneumonitis. In case of suspected Grade 3 or higher pneumonitis, BLENREP should be withheld. If Grade 3 or higher pneumonitis is confirmed, appropriate treatment should be initiated. BLENREP should only be resumed after an evaluation of the benefit and risk. Section 4.8: Albuminuria is added as an AE with frequency Common and incidences 2% at any grade and 1% at grade 3-4 |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                       | For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------|
| IB/0007/G           | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 13/12/2021 | 30/05/2022 | SmPC                  | longer authorised                                                               |
| PSUSA/10869 /202102 | Periodic Safety Update EU Single assessment - belantamab mafodotin product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 02/09/2021 | n/a no     |                       | PRAC Recommendation - maintenance                                               |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/04/2021 | 21/06/2021 | SmPC                  |                                                                                 |
| IB/0002             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/01/2021 | 21/06/2021 | SmPC, Annex II and PL |                                                                                 |
| IB/0001/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/01/2021 | 21/06/2021 | SmPC                  |                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->